Tech Company M&A Transactions
Biscayne Therapeutics Acquisition
On 9/18/2018, Biscayne Therapeutics was acquired by Supernus Pharmaceuticals. Supernus Pharmaceuticals said the transaction price was $183 million.
Transaction Overview
Company Name
Acquired By
Announced On
9/18/2018
Transaction Type
M&A
Amount
$183,000,000
M&A Terms
The transaction, expected to close in the next few weeks, provides for an upfront payment of $15 million payable by Supernus to the current Biscayne security holders. Additional payments payable by Supernus include $73 million contingent on achieving certain development milestones and up to $95 million contingent upon achieving certain sales milestones. Supernus will pay a low single digit royalty on net sales to Biscayne and any applicable royalties to third parties for the use of in-licensed IP. The maximum combined royalty Supernus will pay to all parties is approximately 12%, depending on the IP covering the marketed product and the applicable tiered sales levels.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
4770 Biscayne Blvd. 660
Miami, FL 33137
USA
Miami, FL 33137
USA
Phone
Website
Email Address
Overview
Biscayne Pharmaceuticals is developing novel drugs for cancer and other serious disorders based on analogs of growth hormone-releasing hormone (GHRH) discovered by Dr. Andrew V. Schally, Nobel laureate and renowned drug researcher.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 9/18/2018: SCYTHE venture capital transaction
Next: 9/18/2018: Blippar venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs